A novel oral drug for obstructive sleep apnea (OSA) may work especially well in postmenopausal women. A post hoc analysis of two randomized trials found that aroxybutynin/atomoxetine (AD109) reduced breathing disruptions by 52.8% in postmenopausal women vs. 36.8% in other participants. Since OSA triples in prevalence after menopause and is often missed in this group, the findings could open a simpler treatment path — though experts urge caution given the study's limitations.
A once-daily pill for sleep apnea may hit harder for postmenopausal women
A post hoc analysis of two randomized controlled trials suggests that aroxybutynin/atomoxetine (AD109), a novel oral drug for obstructive sleep apnea (OSA), may be significantly more effective in postmenopausal women than in men or non-menopausal women. Presented at the CHEST 2026 annual meeting, the findings showed a 52.8% relative reduction in the Apnea-Hypopnea Index (AHI) for postmenopausal women vs. 36.8% for others — a meaningful gap for a condition that triples in prevalence after menopause yet is frequently overlooked in this population.
OSA in postmenopausal women is often misattributed to hormonal symptoms like insomnia, fatigue, or depression, delaying diagnosis. Experts say a simple oral option could be a welcome addition — but caution is warranted, as no formal statistical interaction analysis was performed and confounding factors cannot be ruled out.
By the Numbers
Why it matters: If confirmed in larger, prospective studies, AD109 could offer a much-needed, easy-to-use treatment option for a chronically underdiagnosed group — potentially reshaping how clinicians screen and treat OSA in postmenopausal women.
